Palm Beach, FL – August 11, 2022 FinancialNewsMedia.com message comment Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy, and neuroaxonal loss. According to the Multiple Sclerosis International Federation, the number of people with multiple sclerosis worldwide has increased from 2.3 million in 2013 to 2.8 million in 2020. The increasing prevalence of this disease has increased the demand for effective diagnosis and treatment of multiple sclerosis worldwide. Therefore, the government actively supports the treatment of multiple sclerosis. A report of Fortune Business Insights said, “The global multiple sclerosis drug market size was estimated at US$23.68 billion in 2021 during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with lower than expected demand for multiple sclerosis drugs in all regions compared to pre-pandemic levels. Based on our analysis, the market showed a slow growth of 1.2% in 2020 compared to 2019. The growth of the Multiple Sclerosis Drugs market is attributed to the increasing focus on R&D to develop innovative drugs by major market players. For example, in December 2020, Adamas Pharmaceuticals Inc. announced the results of the Phase 3 clinical study of ADS-5102, an investigational amantadine compound for the treatment of MS patients. Additionally, new product launches, increasing government initiatives to improve accessibility of care and treatment, and the increasing prevalence of multiple sclerosis are expected to help expand the market.” Active biotechs in today’s markets include: Pasithea Therapeutics Corp. (NASDAQ:KTTA), BioNTech SE (NASDAQ:BNTX), Amylyx Pharmaceuticals, Inc….